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Abstract
There is a growing recognition that the deformability of particles used for drug delivery plays a
significant role on their biodistribution and circulation profile. Understanding these effects would
provide a crucial tool for the rational design of drug delivery systems. While particles resembling
red blood cells (RBCs) in size, shape and deformability have extended circulation times and
altered biodistribution profiles compared to rigid, but otherwise similar particles, the in vivo
behavior of such highly deformable particles of varied size has not been explored. We report the
fabrication of a series of discoid, monodisperse, low-modulus hydrogel particles with diameters
ranging from 0.8 to 8.9 μm, spanning sizes smaller than and larger than RBCs. We injected these
particles into healthy mice, and tracked their concentration in the blood and their distribution into
major organs. These deformable particles all demonstrated some hold up in filtration tissues like
the lungs and spleen, followed by release back into the circulation, characterized by decreases in
particles in these tissues with concomitant increases in particle concentration in blood. Particles
similar to red blood cells in size demonstrated longer circulation times, suggesting that this size
and shape of deformable particle is uniquely suited to avoid clearance.
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1. Introduction
Crosslinked hydrophilic polymers called hydrogels possess a number of properties which
make them an important class of biomaterials for use in biotechnology and medicine. The
high water content of hydrogels makes them soft and rubbery; physical characteristics
similar to those of soft tissues[1]. Many hydrogels exhibit excellent biocompatibility, likely
as a result of their high water content, causing minimal inflammatory responses, thrombosis,
and tissue damage [2–5]. Many hydrogel properties are controlled to a large extent by the
crosslink density of the gels, including the swelling, cargo release profile and stiffness of the
gels[6, 7]. Because of these properties and their facile control, hydrogels of a range of
structures are used in medical applications ranging from drug delivery agents [6, 7], to tissue
engineering [8] and biosensor coatings [9, 10].
Recently, increasing attention has been directed towards extremely deformable hydrogel
particles for their ability to avoid biological filtration mechanisms in model systems and in
vitro. Low modulus microgel particles were able to traverse pores which were 1/10 their
diameters under pressures relevant to renal filtration, suggesting a clearance mechanism for
deformable nanoparticles[11]. Microparticles resembling red blood cells were more readily
able to traverse microfluidic channels which mimicked the constrictions of capillaries when
crosslink density was lowered[12, 13]. Our previous work demonstrated that hydrogel
particles composed of lightly crosslinked 2-hydroxyethyl acrylate (HEA), which resembled
red blood cells in size and shape, had dramatically altered behavior in vivo in a mouse
model due to their flexibility. Particles made from this hydrogel material with a Young’s
modulus of 7.8 kPa were eliminated from the circulation over 30 times slower than particles
which were only moderately (approximately 8x) stiffer (63.9 kPa), presumably due to
avoidance of filtration in the capillary beds of the lungs, and to some extent, the spleen[13].
The most elastically soft particles demonstrated the ability to deform to bypass physical
barriers encountered in the circulation. Because even slightly less elastic particles (modulus
of 16.9 kPa) had greatly reduced circulation times, a modulus-based threshold for 6 μm
diameter particles to avoid filtration in vivo was inferred[13]. While flexible hydrogel
particles have been shown to have advantageous properties for in vivo applications,
relatively few studies have focused on the in vivo behavior of particles with a modulus in
this biologically relevant range.
The rigidity of hydrogels is typically tuned by adjusting the amount of crosslinker. While
this method provides fairly facile control of hydrogel modulus, increased swelling with
decreasing crosslink density results in difficulty in maintaining identical particle size and
size distribution with changing crosslink density for most particle fabrication methods[1].
However, with the PRINT® (particle replication in non-wetting templates) method[14, 15],
the size and/or shape of the elastomeric molds used in particle fabrication determine the size
and shape of the particles. In this study, the in vivo behavior of monodisperse populations of
extremely soft hydrogel particles was evaluated as particle size was varied in the micron
range while composition and modulus were maintained as constants. We fabricated a series
of monodisperse, low modulus (E = 6.5 kPa) hydrogel particles with diameters of 0.8, 3.8,
6.4 and 8.9 μm. The in vivo circulation profiles and biodistributions of these extremely
deformable particles were examined in wild type mice, providing insights into the behavior
of such low modulus microgels as particle size varies.
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2. Materials and Methods
2.1 Materials
Acryloyl chloride (97%), triethylene glycol (99%), and 2-carboxyethyl acrylate (CEA, 97%)
were purchased from Sigma-Aldrich and used as received. Photoinitiators 2,2-
diethoxyacetophenone (DEAP), and 1-hydroxyl-cyclohexyl phenyl ketone (HCPK) were
purchased from Aldrich and used as received. Poly(ethylene glycol) diacrylate
(PEG4000DA) and methacryloxyethyl thiocarbamoyl rhodamine B (PolyFluor 570) were
purchased from Polysciences, inc. and used as received. Dylight 680 maleimide was
purchased from Thermo Scientific. All other reagents were purchased from Fisher and were
used without further purification unless otherwise noted.
2.2 Synthesis of Hydroxy PEG Acrylate Monomer
Mixtures of hydroxy PEG acrylate and hydroxy PEG diacrylate were obtained by reaction of
triethylene glycol and acryloyl chloride in anhydrous dichloromethane and triethyl amine, as
decribed by Guzman, et al. [16] Briefly, addition of acryloyl chloride proceeded over 3
hours at room temperature and stirred overnight. The salts were removed via filtration and
washed with deionized water. The aqueous phase was washed with diethylether to extract
the monoacrylate. The ether was removed by rotary evaporator, and the product isolated via
column chromatography using a mixture of hexane, ethyl acetate and methanol in a 6:3:1
ratio. Free radical inhibitor 4-methoxy phenol (MEHQ) was added to the product fraction at
500 ppm prior to exhaustive reduced-pressure rotary evaporation yielding a clear, colorless
to pale yellow liquid. The acrylic monomer is referred to as hydroxyl PEG acrylate (HPA).
Characterization is found in the supplemental information.
2.3 Modulus Testing
To measure the mechanical properties of crosslinked HPA hydrogels, macroscopic coupons
of the prepolymer mixtures were polymerized via UV light in a Teflon mold. Approximately
650 μL of freshly prepared prepolymer mixture was pipette into a 2.5 × 2.5 cm square mold.
The mold was placed in a low-intensity UV oven, and nitrogen purged for 3 minutes prior to
curing with UV light. The cross-linked hydrogels were removed from the mold, weighed,
and placed in pH 7.4 phosphate buffered saline (PBS) buffer for 24 hours to fully hydrate.
The coupons were patted dry with paper towels and weighed again prior to sectioning into
approximately 10 mm wide strips with a razor blade for testing with an Instron 5556
Universal Testing Machine (Instron) with a strain rate of 5 mm/min. Young’s modulus was
determined from the initial slope of the resultant stress-strain curves.
2.4 Particle Fabrication
Particles were fabricated using the PRINT process, which has been well described elsewhere
[14, 15]. PRINT molds for these studies were obtained from Liquidia technologies
(Research Triangle Park, NC) and consisted of a thin layer of a patterned, photocured
perfluoropolyether (PFPE) on top of a flexible poly(ethyleneterephthalate) (PET) backing.
For these studies, the pre-polymer mixture was spread onto molds that were chilled to 2–5°C
on a custom built laminator platform. The reduced temperature prevented evaporation of the
pre-polymer solution prior to photo-curing. The filled mold was immediately transferred
into a chilled (~5°C), nitrogen purged UV oven and cured with UV light (λ=365nm, 3
minutes, power ~ 20 mW/cm2).
Particles were transferred from the mold by laminating the filled, cured molds to a PET
sheet which was coated with a thin film of Luvitec (BASF). The particle-filled mold and
Luvitec coating were placed in contact and passed through the nip point of a heated
laminator (180 °F). After cooling briefly, the mold was peeled away from the Luvitec sheet,
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leaving the particles on the Luvitec film. Harvesting of the particles into solution was
accomplished by dissolving the Luvitec layer in water.
The harvesting process leads to well stabilized particles, but leaves an abundance of
dissolved Luvitec in solution. The particles were pelleted via centrifugation at 4 °C (12,000
rpm, 5–10 minutes depending on particle size) and the supernatant removed. The pellet was
resuspended in Dulbecco’s pH 7.4 PBS buffer (Fisher Scientific) and this procedure was
repeated 2–3 times to remove excess Luvitec and any soluble fraction of poly(HPA) or
unreacted monomers.
2.5 Particle Characterization
To determine particle concentration, thermogravimetric analysis (TGA) was used. A sample
of the particle solution was centrifuged exhaustively (14,000 RPM/20 minutes) to pellet the
particles. The supernatant (20 μL) was pipetted to a tared pan and the weight was monitored
on a Perkin Elmer Pyris 1 TGA as the sample was heated and dried, providing the weight of
salts and dissolved polymer in solution. In parallel, a 20 μL sample of the particle solution
was analyzed under identical conditions, with the particle weight determined by subtracting
the weight of salts and polymer in solution from this final weight.
Particles dimensions were determined by analysis of images from a microscope mounted
camera (Zeiss AxioCam MRm) using Zeiss Axiovision LE software and measuring over 50
particles in pH 7.4 PBS buffer, or by dynamic light scattering (DLS) in the case of 0.78 μm
particles using a nano ZS zetasizer (Malvern Instruments). Zeta potentials for particles were
measured on a nano ZS zetasizer (Malvern Instruments) in water.
2.6 In vivo Plasma and Tissue Pharmacokinetic (PK) Studies
PK studies of 0.8, 3.8, 6.4 and 8.9 μm diameter particles were performed in female BALB/c
mice (20–22g). Each particle was administered IV × 1 via a tail vein at 20 mg/kg (particle
dose/body weight). Mice (n=4 per time point) were sacrificed prior to administration, and at
0.2, 0.5, 1, 3, 7, 24, 56, and 104 hours after administration of each particle. From each
mouse, blood was collected (~1 mL) in a heparinized tube via cardiac puncture. In addition,
lungs, liver, kidneys, spleens, heart and a posterior leg (thigh) muscle were obtained after
the blood sample was obtained. Blood and tissue samples were analyzed immediately after
collection. Tissues were not perfused.
2.7 Fluorescent Imaging
The fluorescent signal from the particles in blood and tissues was measured using an IVIS
Lumina fluorescent imager (Caliper Life Sciences) with excitation at 675 nm and emission
measured at 720 nm according to previously described procedures[13]. Blood was pipetted
in 100 μL aliquots to black 96 well plates for analysis on the IVIS Lumina imager. Tissues
were weighed after imaging, and biodistribution was expressed as a function of fluorescent
signal per gram of tissue weight.
2.8 Pharmacokinetics of Particle Clearance from Blood
For determination of pharmacokinetic parameters including alpha and beta half-lives, we fit
the data to a two-compartment model using nonlinear regression analysis (Excel) [13, 17].
The two compartment model assumes that particles are transported between the central and
peripheral compartments with first-order kinetics and that particles are eliminated from the
central compartment with first-order kinetics. The data was fit to Equation 1, where Cp is
the concentration of the particle in the plasma, A and B are hybrid coeffecients, t is the time
component, and a and β are rate constants for the distribution and elimination processes,
respectively.
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Using standard methods and calculations, we estimated various pharmacokinetic parameters,
including at1/2 (half-life of particle distribution), βt1/2 (half-life of particle elimination), VC
(volume of the central compartment), Vdβ (volume of distribution during the elimination
phase), AUC (area under the curve), and CLT (total body clearance).
2.9 Histological Analysis of Tissues
Lung, liver and spleen tissues were frozen on dry-ice shortly after harvesting and 10 μm
frozen sections were prepared for staining. Sections were fixed with 2.5% paraformaldehyde
and stained with 4′,6-diamidino-2-phenylindole. Sections were imaged with a Zeiss 710
confocal microscope using a 63x oil objective.
3. Results and Discussion
3.1 Low Modulus HPA Hydrogels
For the fabrication of low-modulus hydrogel particles of different sizes, we synthesized an
oligo (ethylene glycol) (OEG) functionalized acrylic monomer. The addition of OEG chains
to particles is generally considered useful for in vivo applications and is thought to both
increase particle stability and decrease recognition by the reticuloendothelial system[18–20].
However, long side chains reduce the flexibility of the main polymer chain due to increased
steric bulk, producing hydrogels that are less flexible, with a higher modulus[7]. To balance
these effects, we selected a chain length of 3 ethylene glycol units and attached this to an
acrylic monomer. For the determination of mechanical properties, we added varied amounts
of a 4,000 g/mol PEG diacrylate (PEG4000DA) as a crosslinker and polymerized bulk
coupons.
Based on previous work with low modulus hydrogels[13], an elastic modulus of ≤ 10 kPa
was targeted for HPA based hydrogels. With deformability similar to that of red blood cells
(15–26 kPa)[21, 22], a modulus in the target range should be sufficient to show a large
effect on particle circulation with 6 μm diameter particles. An acid containing monomer (2-
carboxyethyl acrylate, CEA) was included in the hydrogel monomer mixture at 10 % (by
weight) to give the particles a negative charge, thereby decreasing non-specific particle
uptake[23]. Bulk samples of HPA hydrogels containing 10% CEA monomer, 1% 1-
hydroxycyclohexyl phenyl ketone photoinitiator and crosslinked with PEG4000DA were
hydrated in pH 7.4 PBS to simulate physiological conditions and tested with the Instron
tensometer (Table 1). Hydrogels with 0.05% PEG4000DA crosslinker had the desired
properties, with a Young’s modulus of 6.5 ± 1.3 kPa. This formulation was used to fabricate
particles for in vivo testing (Table 2).
3.2 Fabrication and Characterization of HPA Hydrogel PRINT Particles
Low-modulus (E=6.5 kPa) HPA hydrogels included 1% Dylight 680 maleimide for in vivo
imaging, and 0.1% methacryloxyethyl thiocarbonyl rhodamine B for ease of particle
analysis during the PRINT process. Both dyes were incorporated into the hydrogel matrix
via inclusion in the free radical polymerization reaction that formed the particles. Particles
fabricated using discoid PRINT molds with feature diameters of 0.2, 1, 2 and 3 μm, resulted
in hydrated diameters of 0.78, 3.79 ± 0.17, 6.39 ± 0.56, and 8.88 ± 0.47 μm in PBS,
respectively (Table 3).
Fluorescent microscopy was used to measure the diameter of hydrated particles (n=50) for
all except those molded at 0.2 μm. These particles were too small to accurately measure by
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fluorescence microscopy, but were evaluated using dynamic light scattering to determine
their hydrodynamic diameter. The zeta potential of the particles, as measured in water, was
approximately −20 mV in all cases. The particles were suspended in 0.1wt% 2,000 g/mol
poly (vinyl alcohol) in PBS for in vivo applications. Fluorescent images of the particles can
be seen in Figure 1.
3.3 Pharmacokinetic Disposition in Blood
The concentration versus time profiles of the 0.78, 3.8 and 6.4 and 8.9 μm particles in whole
blood are presented in Figure 2. Particle concentration in the blood was determined from
blood drawn via cardiac puncture at each time-point. Serial dilutions of particles in freshly
drawn mouse blood allowed for the generation of standard curves which correlated
fluorescent signal in whole blood to particle concentration. The signal from blood harvested
from dosed mice fell within the linear region of these plots in most cases, with late time-
points falling below quantification limits (where the plot deviated from linearity due
primarily to interference from autofluorescence in blood) for the case of the 8.9 μm
particles.
To evaluate the kinetics of clearance for the 0.78, 3.8 and 6.4 μm diameter particles, we
used a two compartment pharmacokinetic model (Table 4), characterized by a bi-
exponential decrease in particle concentration over time [24], with parameters fit by non-
The fits generated using this method are shown, along with the data, in figure 2. This model,
which has often been appropriate to describe the behavior of particles in the circulation[13,
25], describes an initial (distribution) phase where the particles distribute from the plasma
into various tissues, followed by a late (elimination) phase that describes the ultimate
clearance of particles from the plasma. For small molecules and nanoparticles the
distribution is attributed to extravasation into tissue; because of their size, the distribution of
our hydrogel microparticles may be due to physical entrapment in constricted capillaries (as
in the lung) or tissues with low blood flow (such as the spleen and liver) rather than by an
extravasation process.
The clearance profiles were somewhat similar for each of the particles examined, with much
of the dose distributing to tissues rapidly after injection and slow elimination half-lives.
Elimination half-lives (βt1/2) for the smaller particles, 31 and 60 hours for the 0.78 and 3.8
μm particles, respectively, were shorter than for the red blood cell (RBC) sized 6.4 μm
particles (85 h), suggesting that this size may crucial to the long circulation times of RBCs.
Additionally, the area under the curve (AUC), was more than 3 times greater for the RBC
sized particles than the smaller hydrogels (8.5 compared to 2.5 and 1.7 mg*hr/mL,
respectively), indicating that a much greater amount of particles stayed in the circulation
over time.
The circulation profile of the largest particles examined in this study (8.8 μm) could not be
described by a pharmacokinetic model because these were rapidly cleared below the limits
of quantification, leaving too few data points for such analysis. These particles did not
appear as if their clearance profile would be well described by a standard pharmacokinetic
model due to the increase in particle concentration in blood at 3 and 7 hours, the explanation
of which may require the application of more complicated models[26]. This effect of
increases in particle concentration in the blood at later time points, correlated to decreases in
particle signal in either the lungs or spleen in all cases, and occurred reliably in multiple
studies. This strongly suggests that these deformable particles are physically trapped in these
tissues, and are able to dislodge and re-enter the main circulation before other mechanisms
result in irreversible clearance.
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3.4 Pharmacokinetic Disposition in Tissues
The disposition of particles in various tissues was examined by evaluation of the particle
fluorescence in excised tissues. The smallest particles (hydrodynamic diameter = 0.78 μm)
distributed primarily into the spleen and liver after injection. Particle accumulation in these
tissues increased after injection, peaking 1 hour after dosing at nearly 80% of the recovered
fluorescence (Figure 3). Clearance to the spleen and liver seems to have been the main
mechanism of distribution for these particles, as the initial concentration in the blood
dropped rapidly over the first hour post-dose. Accumulation in the lungs, heart and kidneys
was minor over the course of the study. The particles were highly concentrated in the spleen,
though more total particles were sequestered in the liver. This difference can be seen in
comparing figure 3 and figure 4, which present the biodistribution data on a per tissue and
per gram of tissue basis, respectively. After 104 hours, the particles were largely cleared
from the blood, with only 3.4% of the dose still circulating.
Particles with a hydrated diameters of 3.8 μm distributed primarily into the spleen and lungs
immediately after injection. While signal in the lungs decreased after injection, signal in the
spleen increased, peaking at 3 hours and staying fairly constant or slightly decreasing over
the next 101 hours. These particles accumulated to some extent in the liver over the course
of the study, with signal peaking 24 hours after injection and decreasing slightly thereafter.
Liver accumulation was minor when viewed on a per gram basis (Figure 4). Accumulation
in the kidneys and heart remained low at all times, decreasing over the course of the scan,
possibly due to the small amount of blood remaining in these tissues. Particles were cleared
to low, but still measurable, levels in the blood by the final time-point examined, with 4.1%
of the injected dose in the blood at 104 hours.
Particles with 6.4 μm diameters distributed primarily into the spleen and lungs immediately
after injection with a profile similar to what we observed in previous studies with low
modulus particles of this size[13]. Signal in the lungs decreased after injection to low levels.
Signal in the spleen and liver increased after injection, with signal in the spleen peaking at 3
hours and the signal in the liver peaking later, 7 hours after injection. Signal in the spleen
dipped at the 24 hour time-point, correlating to an increase in signal in the blood. This effect
may have been due to the release of physically entrapped particles from the spleen back into
the circulation. This trend was observed reliably over several experiments and appears to be
characteristic of highly deformable particles of this size. A major function of the spleen is to
sequester older or damaged red blood cells based on their decreasing deformability, as
demonstrated by their ability to navigate narrow fenestrations in this tissue[27]. Older,
stiffer cells spend longer residence times in the macrophage-rich red-pulp, from which they
are eventually cleared. The tissue distribution data suggest that these particles, which share
similar size, shape and deformability with red blood cells, may be cleared in the same
fashion. Accumulation in the kidneys, heart, and muscle tissue remained low at all times,
decreasing over the course of the scan, possibly due to the small amount of blood remaining
in these tissues. At the final time-point examined, 104 hours post-dose, 13.2% of the
injected dose remained in the blood.
The largest particles, with hydrated diameter of 8.8 μm, were sequestered primarily in the
lungs after injection, likely due to their large size compared to the diameter of the capillary
beds in this tissue, and only low amounts of particles remained in the circulation. Particles
cleared from the lungs over the course of the study, with accumulation in the spleen and
liver increasing over time. Liver accumulation was the most significant for these larger
particles compared to the other sizes examined, especially when viewed on a per gram basis
(Figure 3). As with the 6.4 μm diameter particles, a dip in the amount of particles in the
spleen and a corresponding increase in the blood occurred. For these larger particles, this
effect was more dramatic, and happened earlier in the study (7 hours post-dose). These
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particles were largely cleared from the circulation to below quantifiable levels by 24 hours
post injection, correlating to less than 3% of the injected dose.
Histological sections of lung, liver and spleen tissues were taken from mice sacrificed 104
hours after dosing to determine if the particles remained intact in over the course of the
study. Intact particles were detected in the liver and the spleen of mice at the end of the
study for all particle sizes (Supplementary figure S1), though only the largest particles were
detected in the lungs. A more thorough study of the intraorgan distribution of these particles
may further enhance our understanding of the clearance mechanisms for these particles, and
will be the subject of future studies.
Conventional wisdom regarding the design of micro- and nano- particles would predict the
smallest particles in this study to be the longest circulating ones[28], as they should be able
to more easily avoid physical filtration. However, we have observed a much shorter
elimination half-life for these 780 nm particles than for 6.4 μm particles (31 and 85 hours,
respectively). A possible explanation for this relatively rapid clearance is the influence of
particle size on the rate of cellular uptake, with smaller particles more rapidly internalized
[29, 30]. It is possible that these smaller particles were more rapidly recognized and
phagocytosed by macrophages in the liver and spleen, leading to their more rapid clearance
from the circulation. The shorter circulation time of the 3.79 μm particles also lends support
to this argument, as these microparticles would be expected to more readily avoid
sequestration in the fenestrations in the spleen that might entrap the 6.4 μm particles due to
their marginally smaller size, while still large enough to avoid primary clearance in the liver.
Further work will be required to fully understand the different mechanisms of clearance that
act on these highly deformable particles as particle size varies.
4. Conclusions
Particles with extremely high levels of deformability, characterized by a Young’s modulus
of 6.5 kPa, are able to avoid or escape filtration when injected intravascularly in mice.
Evidence of avoidance is clear from the long (>30 hours) elimination half-lives of all but the
largest of these particles. Escape from clearance tissues is also clearly seen, as these
particles tended to accumulate into the spleen over time, reaching a maximum value then
decreasing. The decrease in accumulation in the spleen correlated with an increase in the
concentration of particles in the blood, presumably due to the release of some of the
physically entrapped particles. This was seen most dramatically in the largest of the
microgels studied (8.9 μm), where the particle concentration decreased for the first hour of
the study before increasing at the 3 and 7 hour time points, presumably due to the escape of
particles from the lungs and spleen, which resulted in a corresponding decrease in particle
accumulation. Finally, higher circulation persistence and slower clearance were seen for
deformable particles that resembled red blood cells in size than for both larger and smaller
particles, indicating that this combination of size, shape and deformability results in particles
that are better adapted to the avoidance of natural clearance mechanisms in the body.
The results presented here demonstrate the importance of size and deformability for
determining the biodistribution and circulation persistence of hydrogel particles. This
information is expected to have a large impact on the design of hydrogel particles for
therapeutic or diagnostic applications and to provide a foundation for the use of such highly
deformable particles for drug delivery.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fluorescent images of the particles used for the in vivo studies. The particles have hydrated
diameters of (A) 0.78 μm (B) 3.79 ± 0.17 μm, (C) 6.39 ± 0.56 μm, and (D) 8.88 ± 0.47 μm.
Diameters were measured by dynamic light scattering (A) or by analysis of multiple
fluorescent images (B–D) using Axiovision LE software. Scale bars are 20 μm.
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Change in particle concentration in blood over time for deformable hydrogel particles of
different sizes. Curves generated by application of a two-compartment pharmacokinetic
model are shown with solid lines. The largest of these particles, with hydrated diameters of
8.9 μm, were cleared to concentrations below the limits of quantification after 7 hours and
were not well-described by the pharmacokinetic model due to increases in concentration
before falling under the quantification limit. Each data point represents 4 mice, with error
bars representing one standard deviation. linear regression analysis [17].
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Semi-log plot showing the biodistribution of highly deformable particles of different sizes in
mice over the course of 5 days as measured by the percent of total fluorescence recovered.
The fluorescent signal from the particles in each whole tissue examined is shown for
particles with diameters of (A) 0.78 μm, (B) 3.8 μm, (C) 6.4 μm and (D) 8.9 μm. Lines
have been added to connect the data points for clarity only. Four mice were examined per
time-point, with error bars representing one standard deviation.
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Semi-log plot showing the biodistribution of highly deformable particles of different sizes in
mice over the course of 5 days as measured by the percent of total recovered fluorescent
signal from the particles, and adjusted by the weight of each tissue. Data is shown for
particles with diameters of (A) 0.78 μm, (B) 3.8 μm, (C) 6.4 μm and (D) 8.9 μm. Lines
have been added to connect the data points for clarity only. Four mice were examined per
time-point, with error bars representing one standard deviation.
Merkel et al. Page 14

























Merkel et al. Page 15
Table 1
Mechanical properties of hydroxyl PEG Acrylate (HPA) hydrogels with varying amounts of
PEG4000diacrylate crosslinker and 10% of 2-carboxyethyl acrylate. Swelling ratios were determined from one
bulk sample hydrated for 24 hours in PBS. Modulus and strain at break represent an average value determined
from three samples cut from the bulk gel, with error representing one standard deviation.
% crosslinker (weight) 1 0.5 0.05
E (kPa) 17 ± 2.2 13 ± 1.6 6.5 ± 1.3
% strain at break 53 ± 19 46 ± 7 43 ± 7.5
Swelling ratio (wt) 11.9 12.8 30.0
Swelling ratio (length) 2.4 2.6 3.5
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Table 2




PEG 4000 Diacrylate 0.05
1-hydroxycyclohexyl phenyl ketone 1
methacryloxyethyl thiocarbonyl rhodamine B 0.1
Dylight 680 maleimide 1
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Table 3
Characterization of particles fabricated for in vivo studies. Particles molded from 1, 2 and 3 μm features were
measured by microscopy, with error representing one standard deviation from the mean with n=50 for particle
diameters. Particles molded at 0.2 μm were measured by dynamic light scattering to determine their
hydrodynamic diameter.
Mold diameter Particle Diameter Zeta Potential
0.2 μm 0.78 μm (PDI=0.219) −17.9± 7.8 mV
1 μm 3.79 ± 0.17 μm −22.1 ± 5.7 mV
2 μm 6.39 ± 0.56 μm −17.6 ± 10.8 mV
3 μm 8.88 ± 0.47 μm −22.9 ± 7.47 mV
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Table 4
Pharacokinetic parameters for low modulus hydrogel PRINT particles with increasing diameters. Parameters
were determined from particle concentration in whole blood at times 0.2 –104 hours post-dose using a
standard two-compartment model.
Particle Diameter (μm) 0.78 3.79 6.39
A mg/mL 0.309 0.152 0.109
B mg/mL 0.0353 0.0268 0.0682
α hr−1 2.88 0.76 1.08
β hr−1 0.0224 0.0116 0.00810
αt1/2 hr 0.2 0.9 0.6
βt1/2 hr 31.0 59.6 85.5
VC mL/kg 1.16 2.25 2.26
Vdβ mL/kg 10.60 12.68 5.73
AUC mg*hr/mL 1.69 2.50 8.51
CLT mL/hr/kg 0.24 0.16 0.047
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